文献速递食管与纵隔外科

食管癌新辅助放化疗后30天与90天术后死亡驱动因素

Drivers of 30- and 90-day Postoperative Death After Neoadjuvant Chemoradiation for Esophageal Cancer.
PubMed 文献 · Ann Thorac Surg · 2019-12-14

基于美国国家癌症数据库分析7691例cT3-4/N+食管癌患者,接受新辅助放化疗后食管切除术,30天死亡率为2.9%,90天为7.2%。切缘阳性、鳞癌、年龄≥69岁、30天内再入院及微创中转开放手术均与90天死亡率超过10%相关。

要点

  • 30天死亡率为2.9%,90天死亡率为7.2%。
  • 切缘阳性使30天和90天死亡风险增加一倍以上。
  • 年龄≥69岁、再入院、中转开放手术的90天死亡率均超10%。

核心结论

  • 新辅助放化疗后食管切除术的30天和90天死亡率与随机数据相当。
  • 切缘阳性、鳞癌、年龄69岁及以上、30天内再入院及微创中转开放手术均与90天死亡风险超过10%相关。

研究设计与样本

  • 回顾性队列研究,使用美国国家癌症数据库识别cT3-4/N+食管癌接受新辅助放化疗后食管切除术的患者,共7691例。
  • 采用双变量单变量和多变量回归分析识别30天和90天死亡率的预测因素。

主要发现

  • 30天死亡率为2.9%,90天死亡率为7.2%。
  • 30天内再入院发生率为6.0%。
  • 切缘阳性者30天死亡率5.5% vs 2.7%,90天死亡率14.6% vs 6.8%(均P < .001)。
  • 微创中转开放手术者90天死亡率为12.1%(P < .01)。
  • 年龄69岁及以上者90天死亡率为12.1%(P < .001)。

临床怎么用

  • 对于切缘阳性、鳞癌、年龄≥69岁、30天内再入院或微创中转开放手术的患者,应加强术后90天内的监测与支持治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neoadjuvant chemoradiation, followed by esophagectomy, is a standard of care for locally advanced esophageal cancers. The ChemoRadiOtherapy plus Surgery versus Surgery alone (CROSS) trial reported a 30-day mortality rate of 6%. We sought to evaluate 30- and 90-day mortality in similar patients in the United States and identify predictors of higher mortality rates. METHODS: The National Cancer Database was used to identify patients with cT3-4/N+ esophageal cancers treated with neoadjuvant chemoradiation followed by esophagectomy. Bivariate univariable and multivariable regression analysis was used to identify predictors of 30- and 90-day mortality. RESULTS: We identified 7691 patients. Readmission within 30 days of surgery occurred in 6.0% of patients. Mortality was 2.9% at 30 days and 7.2% at 90 days. Positive surgical margins conferred a more than doubled risk of 30- and 90-day mortality, 5.5% vs 2.7% and 14.6% vs 6.8% (both P < .001). Facility surgical volume impacted 30-day mortality, whereas readmission was associated with 90-day mortality, both exceeding 10% (P = .004 and P = .001, respectively). In patients undergoing minimally invasive surgery converted to open, 90-day mortality was 12.1% (P < .01). For patients 69 years and older, 90-day mortality was also 12.1% (P < .001). Patients who underwent esophagectomy more than 45 days from completion of chemoradiation also had higher 90-day mortality at 8.3% vs 6.2% (P < .001). CONCLUSIONS: Postoperative death at 30 and 90 days after neoadjuvant chemoradiation and esophagectomy appears to be on par with randomized data. Positive surgical margins, squamous cell carcinomas, age 69 and older, readmission within 30 days, and conversion from a minimally invasive operation to an open operation all carry a 90-day mortality risk exceeding 10%.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Horne ZD, Wegner RE, Colonias A, et al. Drivers of 30- and 90-day Postoperative Death After Neoadjuvant Chemoradiation for Esophageal Cancer. Ann Thorac Surg. 2019. PMID: 31846643. doi:10.1016/j.athoracsur.2019.10.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。